Goddard Glenn has filed 10 insider transactions across 1 company since January 2023.
Most recent transaction: a grant/award of 28628 shares of Intellia Therapeutics, Inc. ($NTLA) on March 01, 2024.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Goddard Glenn | EVP, Chief Financial Officer | A | Common Stock | 28628 | $0.00 | 69,213.0000 | 0 | 70.54% | 0.00% |
| March 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Goddard Glenn | EVP, Chief Financial Officer | A | Stock Option (right to buy) | 41316 | $0.00 | 41,316.0000 | 0 | 9999.99% | 0.00% |
| Jan. 3, 2024 | Intellia Therapeutics, Inc. | $NTLA | Goddard Glenn | EVP, Chief Financial Officer | S | Common Stock | 5365 | $29.46 | 40,585.0000 | 0 | 11.68% | 0.00% |
| Jan. 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Goddard Glenn | EVP, Chief Financial Officer | M | Common Stock | 3062 | $0.00 | 45,950.0000 | 0 | 7.14% | 0.00% |
| Jan. 1, 2024 | Intellia Therapeutics, Inc. | $NTLA | Goddard Glenn | EVP, Chief Financial Officer | M | Restricted Stock Unit | 3062 | $0.00 | 3,064.0000 | 0 | 49.98% | 0.00% |
| March 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Goddard Glenn | EVP, Chief Financial Officer | A | Common Stock | 27484 | $0.00 | 42,888.0000 | 0 | 178.42% | 0.00% |
| March 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Goddard Glenn | EVP, Chief Financial Officer | A | Stock Option (right to buy) | 38834 | $0.00 | 38,834.0000 | 0 | 9999.99% | 0.00% |
| Jan. 4, 2023 | Intellia Therapeutics, Inc. | $NTLA | Goddard Glenn | EVP, Chief Financial Officer | S | Common Stock | 2427 | $37.21 | 15,404.0000 | 0 | 13.61% | 0.00% |
| Jan. 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Goddard Glenn | EVP, Chief Financial Officer | M | Common Stock | 3062 | $0.00 | 17,831.0000 | 0 | 20.73% | 0.00% |
| Jan. 1, 2023 | Intellia Therapeutics, Inc. | $NTLA | Goddard Glenn | EVP, Chief Financial Officer | M | Restricted Stock Unit | 3062 | $0.00 | 6,126.0000 | 0 | 33.33% | 0.00% |